

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. No public offer of securities is to be made by the Company in the United States.

Yes!Star 

Yestar Healthcare Holdings Company Limited

巨星醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2393)

US\$200 MILLION 6.9% SENIOR NOTES DUE 2021

(Stock Code: 4508)

**INSIDE INFORMATION
AND
SUSPENSION OF TRADING OF THE NOTES**

This announcement is made by Yestar Healthcare Holdings Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) and 37.47(B) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Listing Rules**”) and the inside information provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 20 July 2021 and 23 July 2021 appended with the RSA (the “**RSA Announcements**”) in relation to the proposed offshore debt restructuring. Unless otherwise defined therein, capitalised terms and expressions used herein shall have the same meanings as those defined in the RSA Announcements.

THE PROPOSED RESTRUCTURING

As mentioned in the RSA Announcements, the Company announced the Proposed Restructuring on 20 July 2021 and encouraged the Noteholders to accede to the RSA.

The Company urges the Noteholders who have not acceded to the RSA to do so and to help avoid material disruptions to the Company's operations and preserve value to all stakeholders. The Company believes that completing the Proposed Restructuring will allow the Group to improve its capital structure and return its focus to daily operation with a view to improving cashflows and liquidity and enhancing stakeholder value.

A copy of the RSA is attached in the announcement of the Company dated 20 July 2021 as Appendix 1 and is available for download at <https://sites.dfkingltd.com/yestar>.

THE NOTES

The Notes will mature on 15 September 2021 (the “**Maturity Date**”). The Company has given careful consideration to the existing and expected future liquidity and performance of the Group and its available sources of financing and currently does not expect that it will be in a position to pay the principal amount of, or the accrued but unpaid interest on, the Notes on the Maturity Date, which will constitute an event of default under the Notes.

SUSPENSION OF TRADING AND DELISTING OF THE NOTES

At the request of the Company, trading of the Notes on the Stock Exchange will be suspended from 9:00 a.m. on 9 September 2021, and will remain suspended until the Maturity Date.

Notice is also given that the Notes will be delisted from the Stock Exchange on the Maturity Date. After withdrawal of listing on the Stock Exchange, Noteholders requiring further information in relation to the Notes or the Proposed Restructuring can contact the Company, the Information Agent or the Company's financial and legal advisers with details set out below.

COMPANY

Floor 8, Block A, Green Land Building
No. 58 Xin Jian East Road
Minhang District, Shanghai
201199, People's Republic of China
Email: wanghong@yesstarnet.com.cn
Attention: Ms. Wang Hong

D.F. King Ltd, as the Information Agent

In London:
65 Gresham Street
London EC2V 7NQ
United Kingdom

In Hong Kong:
Suite 1601, 16/F, Central Tower
28 Queen's Road Central
Hong Kong

Email: yestar@dfkingltd.com
Telephone: +44 20 7920 970 in London or +852 3953 7208 in Hong Kong
Attention: D.F. King Debt Team

Admiralty Harbour Capital Limited, as Company's financial adviser
Suite 1702, Prosperity Tower
39 Queen's Road Central
Central, Hong Kong
Email: yestar@ahfghk.com

Kirkland & Ellis, as Company's legal adviser
26th Floor, Gloucester Tower
The Landmark
15 Queen's Road Central
Central, Hong Kong
Email: yestar@kirkland.com

Further announcement(s) will be made by the Company to inform the shareholders and potential investors of any material development as and when appropriate.

Shareholders and investors are reminded to exercise caution when dealing in the securities of the Company.

By order of the Board
Yestar Healthcare Holdings Company Limited
Hartono James
Chairman, CEO and Executive Director

9 September 2021

As at the date of this announcement, the executive Directors are Mr. Hartono James, Ms. Wang Ying, Ms. Wang Hong, Ms. Liao Changxiang and Mr. Li Bin; the independent non-executive Directors are Dr. Hu Yiming, Mr. Zeng Jinsong and Mr. Sutikno Liky.